Navigation Links
Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
Date:5/11/2011

affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter and ViroPharma to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin and Cinryze®. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees. ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE). ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroP
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
2. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
3. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
5. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
6. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
7. Halozyme Therapeutics Realigns Management
8. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
9. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
10. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... -- Pulse Light Clinic in London,s ... as part of their ongoing research into the condition. They ... their Rosacea. The survey participants were aged between 20 and ... women. The results revealed some rather surprising statistics: ... attempt to visit their GP for Rosacea treatment. ...
(Date:6/30/2015)... 30, 2015 First Choice Wellness Care recently ... Duality and is the only clinic in the greater ... removal treatments. The practice has recently expanded their services ... to showcase their focus in the procedure. They upgraded ... faster ink clearance, and superior service. "We,ve ...
(Date:6/30/2015)... 2015  Avanir Pharmaceuticals, Inc. today announced top-line ... treatment with NUEDEXTA ® was associated with ... affect (PBA) in patients with traumatic brain injury ... characterized by sudden and uncontrollable outbursts of laughing ... brain injury. PRISM II is a phase IV ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... 2011 Fuisz ( www.fuisz.com ) today announced the ... Permitting Stage Door Access to On-Line Vendor Information"). ... "This patent covers a system that allows a customer ... a product supplier database through the on-line vendor,s system ...
... 15, 2011 Cardium Therapeutics (NYSE Amex: ... from the Russian Ministry of Health and Social Development ... Company,s Generx™ (alferminogene tadenovec, Ad5FGF-4) biologic product candidate.  Generx ... for the potential treatment of myocardial ischemia due to ...
Cached Medicine Technology:Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 2Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 3Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 4Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 5Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 6Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 7
(Date:6/30/2015)... ... 2015 , ... iData Research ( http://www.idataresearch.com ), the leading ... policy tracking and analysis service. Reimbursement Tracker ™ enables medical device, dental, ... real-time from hundreds of insurance companies covering over 60,000 policies. , “Policy ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... and communications software, Notify™, for the senior care sector. As an innovator of ... senior housing facilities to become more efficient and offer residents better care. , ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... Wagner, Chief Research and Strategy Officer at Predictive Analytics Reporting (PAR) Framework, and ... Science Foundation (NSF), will provide keynote addresses at the 2015 STEMtech conference in ...
(Date:6/30/2015)... ... 30, 2015 , ... Experts estimate that up to 80% of the world’s ... from a dull, constant ache (chronic) to a sudden sharp pain (acute). In addition ... selective nerve root blocks and rhizotomy treatment, OPTIMAL Pain & Regenerative Medicine now offers ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... the U.S. after a 5-day tour in India. During her stay, she ... with Trivedi Master Wellness™ and Transformational Leader/Internationally Beloved Spiritual Master Mahendra ...
Breaking Medicine News(10 mins):Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2Health News:Eldermark Leap-Frogs other Nurse Call and Communication Systems with Notify 2Health News:Eldermark Leap-Frogs other Nurse Call and Communication Systems with Notify 3Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 2Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 3Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 3Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 2Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 3
... Kyphon Inc.,(Nasdaq: KYPH ) today announced that ... the Foundation for Osteoporosis Research,and Education (FORE) to ... World Osteoporosis Day on Saturday, October 20, 2007. ... to: http://www.prnewswire.com/mnr/kyphon/29938/ To raise ...
... Inc.,(NYSE: SMA ), an independent provider of ... medical markets, announced today the appointment,of John Hynes ... Mr. Hynes will assume responsibility for Symmetry,s ... the UK, Ireland,France and Switzerland. He will also ...
... the newest recipients of the prestigious Hartford Doctoral Fellowship ... the John A. Hartford Foundation, administered by The Gerontological ... Each of the Hartford Doctoral Fellows receives a $50,000 ... home institutions, which enables recipients to more fully concentrate ...
... a rectal thermometer instead, experts urge , WEDNESDAY, Oct. ... methods can,t accurately gauge core body temperatures in athletes ... study warns. , Researchers say rectal thermometers do provide ... deadly. , The study authors noted that correct and ...
... whether it,s time to change cervical cancer screening practices, , , ... human papillomavirus (HPV) -- which causes most cervical cancers -- ... malignancies, two new studies show. , What,s unclear, however, is ... of Pap testing, because it can have a slightly higher ...
... the world , WEDNESDAY, Oct. 17 (HealthDay News) -- ... to identify and catalog genetic similarities and differences among ... scientists from six countries. , The first phase, completed ... of techniques used in the search for genes associated ...
Cached Medicine News:Health News:Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk 2Health News:Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk 3Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 2Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 3Health News:Gerontological Society of America awards new Hartford Doctoral Fellowships 2Health News:HPV Test Bests Pap Smear in Studies 2Health News:HPV Test Bests Pap Smear in Studies 3
... D-Type can combine a number of ... microplates on a simple to use ... is a multifunctional stand-alone device but ... robotic systems. Custom and standard add-on ...
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
Smith & Nephew's CDS System is developed exclusively for discography., Developed exclusively for discography, it is the first system designed to measure true disc pressure and record real-time proce...
The Maxi-Therm® lite hyper-hypothermia water blankets from Cincinnati Sub-Zero take conductive warming and cooling therapy to a new, softer level. These blankets are soft, lightweight, and remai...
Medicine Products: